Effectiveness of a Combination of Trimetazidine With One Hemodynamic Agent in Patients Recently Diagnosed With Stable Angina and Still Symptomatic Despite First Line Hemodynamic Therapy

Launched by SERVIER AFFAIRES MÉDICALES · Mar 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a new treatment for patients who have recently been diagnosed with stable angina, a condition that causes chest pain due to reduced blood flow to the heart. Specifically, the trial is looking at how well a combination of a medication called trimetazidine and a standard heart medicine works for people who are still experiencing symptoms despite being on first-line treatments, like beta-blockers or calcium channel blockers. The study will measure how this combination affects patients' angina symptoms, their ability to perform physical activities, and their overall quality of life using a specific questionnaire.

To be eligible for this trial, participants need to be at least 18 years old and have been diagnosed with stable angina. They should also be currently taking one of the standard heart medications but still have symptoms. Patients who are pregnant, breastfeeding, or have certain health conditions that prevent them from taking trimetazidine will not be able to participate. Those who join the study will be asked to complete questionnaires about their symptoms and treatment experience. This information will help researchers understand how well the new treatment works and improve care for others with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male and female recently diagnosed symptomatic stable Angina patients
• • Age ≥18 years old
• • Patient already treated by one first line antianginal haemodynamic agent (ß-blocker or Ca-channel blocker) (according to CCS management guidelines 2019) and still symptomatic after initiation of this antianginal treatment.
• • Patient for whom the physician intends to prescribe trimetazidine based on her/his daily medical practice in the management of symptomatic Angina pectoris, respecting the SmPC in force in the country. Such treatment decision must be taken independently from the participation of the patient in the study.
• • Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
• Exclusion Criteria:
• • Any contra-indication to trimetazidine according to SmPC
• • Patient already treated with trimetazidine before entry into the study.
• • Pregnancy or intention to become pregnant or lactating women during the study.